@article { , title = {A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease}, abstract = {Objectives: To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). Methods: Patients with mild to moderate AD from 14 European centres were randomised to receive open-label donepezil (up to 10 mg once daily) or galantamine (up to 12 mg twice daily) for 12 weeks, according to the approved product labelling. Physicians and caregivers completed questionnaires rating satisfaction with treatment/ease of use in daily practice. Secondary assessments were the ADAS-cog, the MMSE, and the DAD scale to assess ADL. Tolerability was evaluated by reporting adverse events (AEs). Results: Both physicians and caregivers reported significantly greater overall satisfaction/ease of use for donepezil (n = 64) compared with galantamine (n = 56) at weeks 4, 12, and endpoint (week 12 LOCF; all p-values}, doi = {10.1002/gps.1038}, issn = {0885-6230}, issue = {1}, journal = {International Journal of Geriatric Psychiatry}, pages = {58-67}, publicationstatus = {Published}, publisher = {Wiley}, url = {https://uwe-repository.worktribe.com/output/1063764}, volume = {19}, keyword = {donepezil, galantamine, Alzheimer's disease, dementia}, year = {2004}, author = {Jones, Roy W. and Soininen, Hilkka and Hager, Klaus and Aarsland, Dag and Passmore, Peter and Murthy, Anita and Zhang, Richard and Bahra, Ranbir} }